Danaher Corporation is rated Buy with a target price of $250, implying 10.5% upside from $226.25. DHR's strong Q3 execution featured 4.5% revenue growth, margin expansion to 37.2%, and robust free ...
Regtechtimes on MSN
Top 6 CROs in Australia (2025): Why Ingenū is setting a new benchmark
Australia has become one of the fastest-growing destinations for clinical research. With high-quality healthcare infrastructure, diverse patient populations, and streamlined ethics approvals that can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback